Nanobiotix SA closed a private placement of 1,596,527 new shares priced at €15.75 apiece to raise €25.1 million for the development of its cancer treatment NBTXR3.
The shares issued represent 9.99% of the French company.
Nanobiotix completes €25.1M private placement
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021
Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective
Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective
Nanobiotix completes €25.1M private placement
- Author Kshitiz Goliya
- Theme Healthcare & Pharmaceuticals
- Author
- Kshitiz Goliya
- Theme
- Healthcare & Pharmaceuticals